CA2246418A1 - Neovascularization inhibitor - Google Patents
Neovascularization inhibitor Download PDFInfo
- Publication number
- CA2246418A1 CA2246418A1 CA002246418A CA2246418A CA2246418A1 CA 2246418 A1 CA2246418 A1 CA 2246418A1 CA 002246418 A CA002246418 A CA 002246418A CA 2246418 A CA2246418 A CA 2246418A CA 2246418 A1 CA2246418 A1 CA 2246418A1
- Authority
- CA
- Canada
- Prior art keywords
- neovascularization
- endothelial cells
- tranilast
- cells
- microvascular endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
Abstract
A neovascularization inhibitor containing as the active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by chemical formula (I) or pharmacologically acceptable salts thereof, which has the activities of depressing the growth and migration of human capillary endothelial cells and the activity of inhibiting the canalization of the same, thus being useful as preventives and remedies for diseases caused by neovascularization, such as diabetic retinopathy, senile discoid macular degeneration, neovascular glaucoma, and rheumatic arthritis.
Description
DESCRIPTION
NEOVASCULARIZATION INHIBITOR
Technical Field The present invention relates to a pharmaceutical composition which is useful as a neovascularization inhibitor.
More particularly, the present invention relates to an agent for the prevention ortreatment of diseases associatedwith neovascularization which comprises as the active ingredient N- (3,4-dimethoxyc;nn~moyl)anthranilic acid represented by the formula:
CH30~,CONH
CH30~ HOOC
or a p~rm~ceutically acceptable salt thereof.
As diseases associated with neovascularization, various diseases which occur by participation of neovascularization as one of the cause, for example, diabetic retinopathy, senile discoid macular degeneration, retinopathy of prematurity, sickle-cell retinopathy, retinal vein occlusion, neovascularization after corneal transplantation or cataract extraction, neovascular glaucoma, rubeosis iridis, rheumatic arthritis, psoriasis, scleredema, tumors, overgrowth o~
capillary blood vessels in atherosclerosis adventitia and corneal neovascularization caused by long wear of cantact lens can be illustrated.
. CA 02246418 1998-07-31 Background Art In general, neovascularization is phenomena accompanying degradation of the basement membrane by proteolytic enzymes, chemotaxis and proliferation of endothelial cells, tube formation by endothelial cell differentiation andreorganization of blood vessels. Neovascularization occurs in luteinization and placentation physiologically and in the diseases described above pathologically. For example, in retinopathy, retinal tissues lying between preexisting basement membrane around retinal vessels and vitreous are degraded. Then, endothelial cells of preexisting vessels migrate from junctions of the degraded retinal tissues and endothelial cells proliferate to fill up spaces between the endothelial cells migrated, and the endothelial cells migrated to vitreoretina reorganize new vessels, leading to neovascularization.
Neovascularization is correlated with various diseases, and, for example, neovascularization plays a close part in the process of the onset and progress of the above diseases.
Therefore, extensive studies to find compounds havi~g an inhibitory activity on neovascularization have been actively promoted for the prevention or treatment of these diseases.
Although, for example, neovascularization inhibitors such as fumagillin analogues, which are microbial metabolites having an 26 inhibitory activity on endothelial cell proliferation, tetracycline antibiotics, which can inhibit a collagenase activity, and microorganism-derived D-gluco-galactan sulfate, which can interfere with binding of heparin-binding angiogenic factors to their receptors, are known, there is no satisfying drug clinically. In addition, there is no procedure enough to 5 treat the above diseases. Specially, if patients with diabetic retinopathy do not undergo surgical treatment, involution of neogenetic vessels can not be observed, and therefore, visual loss caused by a discharge of blood from neogenetic vessels has become a problem. Thus, development of drugshaving an excellent effect on neovascularization has been greatly desired.
N-(3,4-Dimethoxyci nn~moyl ) anthranilic acid (generic name: Tranilast) represented by the above formula (I) of the present invention has beenused widely as a drug for thetreatment ofallergic disorderssuchasbronchialasthma, allergicrhinitis, atopic dermatitis and allergic conjunctivitis, and cutaneous disorders such as keloid and hypertrophic scar. For example, it has been known that Tranilast has inhibitory activities on chemical mediator release caused by an allergic reaction, excessive collagen accumulation by fibroblast cells incutaneous tissues and excessive proliferation of smooth muscle cells in coronary artery vessels.
However, it is disclosed in no way that Tranilast suppresses proliferation and chemotaxis of microvascular endothelial cells and tube formation of microvascular endothelial cells, and it is not known at all that Tranilast is useful as a neovascularization inhibitor.
Disclosure of Invention The present invention relates to a neovascularization inhibitor which comprises as the active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the formula:
CH30~,CONH ~3 ( I ) or a pharmaceutically acceptable salt thereof.
The present invention relates to a method ~or the prevention and treatment of diseases associated withneovascularization which comprises administering N-(3,4-dimethoxyc;nn~m~yl)anthranilic acid represented by the above formula (I) or a pharmaceutically acceptable salt thereof.
The present invention relates to a use of N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the above formula (I) or a pharmaceutically acceptable salt thereof ~or the manufacture of a p~rm~ceutical composition for the prevention and treatment of diseases associated with neovascularization.
Furthermore, the present invention relates to a use of N-(3,4-dimethoxyc;nn~m~yl)anthranilic acid represented by the above formula (I) or a pharmaceutically acceptable salt thereof as a neovascularization inhibitor.
srief Description of Drawings Figure 1 is a graph illustrating the inhibitory effect of Tranilast on proliferation of human microvascular endothelial cells. The axis of the ordinates shows the number of human microvascular endothelial cells (x 10 cells), and the axis of the abscissas shows concentrations of Tranilast (~ g/ml). The symbols * and * *in the graph show the significantly difference at p<0.05 and p<0.01, respectively.
Figure 2 is a graph illustrating the inhibitory effect of Tranilastonchemotaxisofhumanmicrovascularendothelialcells.
The axis of the ordinates shows the number of human microvascular endothelial cells migrated (cells/visual field), and the axis oftheabscissasshowsconcentrationsofTranilast (~ g/ml). The symbol* * in the graph shows the significantly difference at p<O . 0 1 .
Figure 3 is a graph illustrating the inhibitory effect of Tranilast on tube formation of human microvascular endothelial cells. The axis o~ the ordinates shows the number of network of tube formed (number), and the axis of the abscissas shows concentrations ofTranilast (~ g/ml). Thesymbol* *i~ thegraph shows the significantly difference at p<0.01.
Figure 4 is a graph illustrating the inhibitory effect of Tranilast on tube formation of human microvascular endothelial cells. The axis of the ordinates shows the mean length of tube structure formed (mm), and the axis of the abscissas shows 2~ concentrations of Tranilast (~ g/ml). The symbols * and * * in the graph show the significantly difference at p<0.05 andp<0.01, respectively.
Best Mode for carryinsJ Out the Invention The presentinventors havebeen extensively studiedto find compounds having an inhibitory activity on neovascularization.
As a result, it was ~ound that N-(3,4-dimethoxyc;nn~moyl)-anthranilic acid (generic name: Tranilast) represented by the above formula (I) has remarked inhibitory e~fects on proli~eration o~ human microvascular endothelial cells, chemotaxis o~ human microvascular endothelial cells and tube formation o~ human microvascular endot~el;~l cells, and there~ore, isextremelyuse~ul asaneovascularization inhibitor, thereby ~orming the basis of the present invention.
Accordingly, the present inventors con~irmed that Tranilast signi~icantly suppressed proli~eration o~ human microvascular endothelial cells in the in vi tro cell proli~eration inhibitory activity test using humanmicrovascular endothelial cells.
The present inventors also con~irmed that Tranilast significantly suppressed chemotaxis o~ human microvascular endothelial cells in the in vitro cell chemotaxis inhibitory activity test using human microvascular endothelial cells.
Furthermore, the present inventors also con~irmed that Tranilast signi~icantly inhibited tube ~ormation o~ human 2B microvascular endothelial cells in the in vi tro cell tube ~ormation inhibitory activity test using human microvascular endothelial cells.
As a consequence, Tranilast has excellent inhibitory ef~ects on proliferation and chemotaxis in human microvascular endothelial cells, and therefore, is a compound being useful as 6 a neovascularization inhibitor. Furthermore, Tranilast has an excellent inhibitory effect on tube formation of human microvascular endothelial cells, and therefore, is a compound being extremely useful as an agent for the prevention and treatment of diseases associated with neovascularization.
Therefore, pharmaceutical compositions which are useful as agents for the preventionand treatment of diseases associated with neovascularization can be prepared by comprising as the active ingredient Tranilast or a pharmaceutically acceptable salt thereof.
1~ Various methods for the preparation of Tranilast and pharmaceutically acceptable salts thereof are known (Japanese Patent Application Publication (kokoku) No.Sho.56-40710; ibid.
No.Sho.57-36905; ibid. No.Sho.58-17186; ibid. No.Sho.58-48545;
ibid. No.Sho.58-55138; ibid. No.Sho.58-55139; ibid. No.Hei.
01-28013; ibid. No.Hei.01-50219; ibid. No.Hei.03-37539 etc.).
For example, Tranilast and pharmaceutically acceptable salts thereof can be prepared by allowing a reactive functional derivative such as acid halide and acid anhydride of 3,4-dimethoxyc;nn~m~yl acid represented by the formula:
2~
CHaO~ ( I I ) to react with anthranilic acid represented by the formula:
~ (III) COOH
in the usual way, and if desired, converting the resulting compound into a salt thereof.
As examples of pharmaceutically acceptable salts of Tranilast, salts with inorganic bases such as a sodium salt and a potassium salt, salts formed with organic amines such as morpholine, piperazine and pyrrolidine and salts formed with 1~ amino acids can be illustrated.
When the pharmaceutical compositions of the present invention areemployed in thepractical treatment, various dosage ~orms of pharmaceutical compositions can be used depending upon usage. As examples ofsuch dosage forms,powders, granules, fine granules, dry sirups, tablets, capsules, ointments, injections, eye drops and the like can be illustrated.
These pharmaceutical compositions can be formulated by admixing, diluting or dissolving occasionally with appropriate pharmaceutical additives such as excipients, disintegrators, binders, lubricants, diluents, buffers, isotonicities, antiseptics, moistening agents, emulsifiers, dispersing agents, stabilizing agents and dissolving aids in accordance with conventional methods and formulating in the usual way depending upon the dosage forms.
For example, powders can be formulated by admixing well Tranilast represented by the formula (I) or a pharmaceutically acceptable salt with appropriate excipients, lubricants and the like occasionally.
Tablets can be formulated by admixing Tranilast or a pharmaceutically acceptable salt with appropriate excipients, disintegrators, binders, lubricants and the like occasionally, and pressing the mixture in the usual way. The tablets also can be coated to provide film-coated tablets, sugar-coated tablets, enteric coating tablets and the like.
For example, capsules can be formulated by admixing well appropriate excipients, lubricants and the like occasionally, and filling the mixture in capsules. Capsules can be also formulated by forming granules or fine granules in the usual way, and fi1ling the granules or fine granules in capsules.
Ointments can be used as eye ointments.
Injections can be injected directly into diseased tissues such as cornea and vitreous or their adjacent tissues by using a fine needle, and can be also used as intraocular perfusate.
The pharmaceutical compositions of the present invention can be administered as sustained release preparations. For example, Tranilast preparation is incorporated into pellet or microcapsule of sustained release polymer as a sustained release preparation, andthe pelletormicrocapsule is surgically planted 2~ into tissues to be treated. As examples o~ sustained release polymers, ethylene-vinylacatate copolymer, polyhydro-metacrylate, polyacrylamide, polyvinylpirrolidone, methylcellulose, lactic acid polymer, lactic acid-glycolic acid copolymer and the like can be illustrated, and preferably, biodegradable polymer such as lactic acid polymer and lactic acid-glycolic acid copolymer can be illustrated.
When the pharmaceutical compositions of the present invention are employed in the practical treatment, the dosage of Tranilast or a pharmaceutically acceptable salt thereof as the active ingredient is appropriately decided depending on the body weight, age, sex, degree of symptoms and the like of each patient to be treated, which is ap~roximately within the range of from 100 to 1,000 mg per day per adult human in the case of oral ~m;n;stration and approximately within the range of from 20 ~ g to 300 mg per day per adult human in the case of parenteral administration.
The doseofTranilastor apharmaceutically acceptablesalt thereof can be appropriately increase and decrease depending on the type of diseases, degree of symptoms of each patient to be treated and therapeutic value.
Example Thepresentinventionis furtherillustratedinmoredetail by way of the following Examples.
26 Study to confirm inhibitory effect on neovascularization Example 1 Inhibition of proliferation of human microvascular endothelial cells Culture of human microvascular endothelial cells Normal human dermal microvascular endothelial cells (Cell Systems Corporation) were subcultured in a medium (MVE medium, Cell Systems Corporation) for endothelial cell culture and used for the study. At the logarithmic growth phase, the medium was aspirated and cells were washed with phosphate-buffered saline (PBS(-)) which was added gentlely. Then, the PBS(-) was aspirated, analiquotofO.25% trypsinsolutioncontainingO.02 %
EDTA was added to the culture plate, and the morphology of cells was observed under a phase-contrast microscopy. When cellswere going to be round, an equal value of MVE medium was added to the trypsin solution to stop the action of trypsin. Attached cells 16 were harvested from the plate by pipetting the medium using a slender pasture pipette. Cell suspension was transferred into spit, then medium was added to the spit, and the cell suspension was mixed about 20 times vigorously by pipetting with a pasture pipete and centrifuged at 100-llOxg for 1 minute. A~ter the supernatant was discarded, fresh medium was added to the precipitate, and cell suspension was preparèd by pipetting using a pasture pipete. Number of viable cells in an aliquot of the suspension was counted under a phase-contrast microscopy using a hemocytometer. Cell concentration was adjusted to 2 x 10 26 cells/ml.
Preparation of test drug Tranilast was added to 1 % a~ueous sodium bicarbonate solution to prepare 0.55 % solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and B diluted with MVE medium to a final prescribed concentration.
Experimental method Cell suspension (1 ml) was added to collagen-coated 6-well plate(Toyobo Engineering Co., Ltd.) and cultured at 37 ~C
under a humidified atmosphere of 5 % CO2 in air. After 1 day, the medium was aspirated, cells were washed with PBS(-), and 1 ml of fresh medium and 0.1 ml of various concentrations of Tranilast solution were added to the plate and the plate was incubated for further 2 days. After incubation, the medium was aspirated, cells were washed with PsS(-), and then 1 ml of 0.25 %
trypsin solution cont~ln;ng 0.02% EDTA was added to the plate.
After harvestingcellsfrom theplate bypipettingusing apasture pipete, number ofviable cellswas countedusing ahemocytometer.
~ Assessment of effect Mean and standard variation value o~ each group were calculated. Statistical analysis of significance was performed by a one-way analysis of variance and statistical significance was confirmed. Thereafter, analysis of significance between 2B groups was performed by Dunnett's multiple test.
Results As shown in Figure 1, Tranilast significantly suppressed the proliferation of human microvascular endothelial cells in a concentration-dependent manner.
Example 2 Inhibition of chemotaxis of human microvascular endothelial cells ~ Culture of human microvascular endothelial cells According to the method of Example 1 ~, human microvascular endothelial cells were cultured to prepare a cell suspension. Number of viable cells was counted under a phase-contrast microscopy using a hemocytometer and cell concentration was adjusted to 2 x 10 cells/ml.
Preparation of test drug Tranilast was added to 1 % aqueous sodium bicarbonate solution to prepare 0.55 % solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and diluted with DMEM + Ham (1 : 1) medium to a prescribed final concentration.
Experimental method Chemotaxis of human dermal microvascular endothelial cells (prepared in ~) to vascular endothelial growth factor (VEGF) was studied using a 96-well micro chemotaxis chamber (Neuro Probe Inc.). An aliquot (32 ~ 1) of DMEM + Ham (1:1) medium containing 100 ng/ml of VEGF, 0.1 % bovine serum and various concentrations ofTranilast wasadded tothe lowercavity of the chemotaxis chamber. An aliquot (50 ~ 1) of medium containing cell suspension and Tranilast was added to the upper cavity of the chamber. Polycarbonate filter (10 ~ m thickness with 8 ~ m pore size, Neuro Probe Inc.) coated with type-l collagen was used for the chemotaxis membrane. The chemotaxis chamber was incubated at 37 ~C for 5 hours under a humidified atmosphere of 5 % C02 in air. Cells migrated to the lower side of the filter were fixed with 90 % ethanol, and stained with Diff-Quick (Baxter Diagnostics Inc.). Number of migrated cells was counted in 5 random fields at x 400 magnification under a phase-contrast microscopy and mean chemotaxis cell number was calculated.
Assessment of effect Mean and st~n~rd variation value of each group were calculated. Statistical analysis of significance was performed by a one-way analysis of variance and statistical significance was confirmed. Thereafter, analysis of significance between groups was performed by Dunnett's multiple test.
~ Results 2~ As shown in Figure 2, Tranilast significantly suppressed the chemotaxis of human microvascular endothelial cells in a concentration-dependent manner.
Example 3 Tube formation o~ human microvascular endothelial cells 6 ~ Culture of human microvascular endothelial cells According to the method of Example 1 0, human microvascular endothelial cells were cultured to prepare a cell suspension. Number of viable cells was counted under a phase-contrast microscopy using a hemocytometer and cell concentration was adjusted to 4 x 10 cells/ml.
~Preparation of test drug Tranilast was added to 1~ aqueous sodium bicarbonate solution to prepare 0.5 ~ solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and diluted with MVE medium to a prescribed final concentration.
~Experimental method An aliquot (0.25 ml) of matrigel (10 mg/ml, Becton Dickinson Labware) wasadded to a 24-wellculture plate (Corning) and was then allowed to solidify by incubation at 37 ~C for 1 hour. Suspension (0.25 ml) of human microvascular endothelial cells (4 x 10 cells) and MVE medium (0.25 ml) containing various concentrations of Tranilast were added onto the gel. After 18 hours incubation at 37 ~C, 5 random fields of one well were observed at x lOOmagnificationusingaphase-contrast microscopy and the number of ~ormed network was counted.
Result As shown in Figure 3, number of the formed network was significantly reduced i~ a concentration-dependent manner.
Example 4 Tube ~ormation of human microvascular endothelial cells ~ Culture of human microvascular endothelial cells According to the method of Example 1 ~, human microvascular endothelial cells were cultured to prepare a cell suspension. Number of viable cells was counted under a phase-contrast microscopy using a hemocytometer and cell concentration was adjusted to 4 x 10 cells/ml.
Preparation of test drug Tranilast was added to 1% a~ueous sodium bicarbonate solution to prepare 1.0 % solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and diluted with MVE medium to a prescribed final concentration.
Experimental method An ali~uot (0.25 ml) of matrigel (10 mg/ml, Becton Dickinson Labware) wasadded toa 24-wellculture plate (Corning) and was then allowed to solidify by incubation at 37 ~C for 1 hour. Suspension (0.25 ml) of human microvascular endothelial cells (4 x 10 cells) and MVE medium (0.25 ml) containing various concentrations of Tranilast were added onto the gel. After 18 hours incubation at 37 ~C, 5 random fields of one well were photographed at x 40 magnification using a phase-contrast microscopy. The lengths of the tube structures were measured and the mean value was calculated.
Result As shown in Figure 4, the length of the tube strucure was significantly reduced in a concentration-dependent manner.
Industrial Applicability A pharmaceutical composition comprising as the active ingredient ~ranilast has remarked inhibitory effects on 1~ proliferation and chemotaxis o~ human microvascular endothelial cellsandtubeformationofhumanmicrovascularendothelial cells, and there~ore, is extremely effective as a neovascularization inhibitor.
NEOVASCULARIZATION INHIBITOR
Technical Field The present invention relates to a pharmaceutical composition which is useful as a neovascularization inhibitor.
More particularly, the present invention relates to an agent for the prevention ortreatment of diseases associatedwith neovascularization which comprises as the active ingredient N- (3,4-dimethoxyc;nn~moyl)anthranilic acid represented by the formula:
CH30~,CONH
CH30~ HOOC
or a p~rm~ceutically acceptable salt thereof.
As diseases associated with neovascularization, various diseases which occur by participation of neovascularization as one of the cause, for example, diabetic retinopathy, senile discoid macular degeneration, retinopathy of prematurity, sickle-cell retinopathy, retinal vein occlusion, neovascularization after corneal transplantation or cataract extraction, neovascular glaucoma, rubeosis iridis, rheumatic arthritis, psoriasis, scleredema, tumors, overgrowth o~
capillary blood vessels in atherosclerosis adventitia and corneal neovascularization caused by long wear of cantact lens can be illustrated.
. CA 02246418 1998-07-31 Background Art In general, neovascularization is phenomena accompanying degradation of the basement membrane by proteolytic enzymes, chemotaxis and proliferation of endothelial cells, tube formation by endothelial cell differentiation andreorganization of blood vessels. Neovascularization occurs in luteinization and placentation physiologically and in the diseases described above pathologically. For example, in retinopathy, retinal tissues lying between preexisting basement membrane around retinal vessels and vitreous are degraded. Then, endothelial cells of preexisting vessels migrate from junctions of the degraded retinal tissues and endothelial cells proliferate to fill up spaces between the endothelial cells migrated, and the endothelial cells migrated to vitreoretina reorganize new vessels, leading to neovascularization.
Neovascularization is correlated with various diseases, and, for example, neovascularization plays a close part in the process of the onset and progress of the above diseases.
Therefore, extensive studies to find compounds havi~g an inhibitory activity on neovascularization have been actively promoted for the prevention or treatment of these diseases.
Although, for example, neovascularization inhibitors such as fumagillin analogues, which are microbial metabolites having an 26 inhibitory activity on endothelial cell proliferation, tetracycline antibiotics, which can inhibit a collagenase activity, and microorganism-derived D-gluco-galactan sulfate, which can interfere with binding of heparin-binding angiogenic factors to their receptors, are known, there is no satisfying drug clinically. In addition, there is no procedure enough to 5 treat the above diseases. Specially, if patients with diabetic retinopathy do not undergo surgical treatment, involution of neogenetic vessels can not be observed, and therefore, visual loss caused by a discharge of blood from neogenetic vessels has become a problem. Thus, development of drugshaving an excellent effect on neovascularization has been greatly desired.
N-(3,4-Dimethoxyci nn~moyl ) anthranilic acid (generic name: Tranilast) represented by the above formula (I) of the present invention has beenused widely as a drug for thetreatment ofallergic disorderssuchasbronchialasthma, allergicrhinitis, atopic dermatitis and allergic conjunctivitis, and cutaneous disorders such as keloid and hypertrophic scar. For example, it has been known that Tranilast has inhibitory activities on chemical mediator release caused by an allergic reaction, excessive collagen accumulation by fibroblast cells incutaneous tissues and excessive proliferation of smooth muscle cells in coronary artery vessels.
However, it is disclosed in no way that Tranilast suppresses proliferation and chemotaxis of microvascular endothelial cells and tube formation of microvascular endothelial cells, and it is not known at all that Tranilast is useful as a neovascularization inhibitor.
Disclosure of Invention The present invention relates to a neovascularization inhibitor which comprises as the active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the formula:
CH30~,CONH ~3 ( I ) or a pharmaceutically acceptable salt thereof.
The present invention relates to a method ~or the prevention and treatment of diseases associated withneovascularization which comprises administering N-(3,4-dimethoxyc;nn~m~yl)anthranilic acid represented by the above formula (I) or a pharmaceutically acceptable salt thereof.
The present invention relates to a use of N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the above formula (I) or a pharmaceutically acceptable salt thereof ~or the manufacture of a p~rm~ceutical composition for the prevention and treatment of diseases associated with neovascularization.
Furthermore, the present invention relates to a use of N-(3,4-dimethoxyc;nn~m~yl)anthranilic acid represented by the above formula (I) or a pharmaceutically acceptable salt thereof as a neovascularization inhibitor.
srief Description of Drawings Figure 1 is a graph illustrating the inhibitory effect of Tranilast on proliferation of human microvascular endothelial cells. The axis of the ordinates shows the number of human microvascular endothelial cells (x 10 cells), and the axis of the abscissas shows concentrations of Tranilast (~ g/ml). The symbols * and * *in the graph show the significantly difference at p<0.05 and p<0.01, respectively.
Figure 2 is a graph illustrating the inhibitory effect of Tranilastonchemotaxisofhumanmicrovascularendothelialcells.
The axis of the ordinates shows the number of human microvascular endothelial cells migrated (cells/visual field), and the axis oftheabscissasshowsconcentrationsofTranilast (~ g/ml). The symbol* * in the graph shows the significantly difference at p<O . 0 1 .
Figure 3 is a graph illustrating the inhibitory effect of Tranilast on tube formation of human microvascular endothelial cells. The axis o~ the ordinates shows the number of network of tube formed (number), and the axis of the abscissas shows concentrations ofTranilast (~ g/ml). Thesymbol* *i~ thegraph shows the significantly difference at p<0.01.
Figure 4 is a graph illustrating the inhibitory effect of Tranilast on tube formation of human microvascular endothelial cells. The axis of the ordinates shows the mean length of tube structure formed (mm), and the axis of the abscissas shows 2~ concentrations of Tranilast (~ g/ml). The symbols * and * * in the graph show the significantly difference at p<0.05 andp<0.01, respectively.
Best Mode for carryinsJ Out the Invention The presentinventors havebeen extensively studiedto find compounds having an inhibitory activity on neovascularization.
As a result, it was ~ound that N-(3,4-dimethoxyc;nn~moyl)-anthranilic acid (generic name: Tranilast) represented by the above formula (I) has remarked inhibitory e~fects on proli~eration o~ human microvascular endothelial cells, chemotaxis o~ human microvascular endothelial cells and tube formation o~ human microvascular endot~el;~l cells, and there~ore, isextremelyuse~ul asaneovascularization inhibitor, thereby ~orming the basis of the present invention.
Accordingly, the present inventors con~irmed that Tranilast signi~icantly suppressed proli~eration o~ human microvascular endothelial cells in the in vi tro cell proli~eration inhibitory activity test using humanmicrovascular endothelial cells.
The present inventors also con~irmed that Tranilast significantly suppressed chemotaxis o~ human microvascular endothelial cells in the in vitro cell chemotaxis inhibitory activity test using human microvascular endothelial cells.
Furthermore, the present inventors also con~irmed that Tranilast signi~icantly inhibited tube ~ormation o~ human 2B microvascular endothelial cells in the in vi tro cell tube ~ormation inhibitory activity test using human microvascular endothelial cells.
As a consequence, Tranilast has excellent inhibitory ef~ects on proliferation and chemotaxis in human microvascular endothelial cells, and therefore, is a compound being useful as 6 a neovascularization inhibitor. Furthermore, Tranilast has an excellent inhibitory effect on tube formation of human microvascular endothelial cells, and therefore, is a compound being extremely useful as an agent for the prevention and treatment of diseases associated with neovascularization.
Therefore, pharmaceutical compositions which are useful as agents for the preventionand treatment of diseases associated with neovascularization can be prepared by comprising as the active ingredient Tranilast or a pharmaceutically acceptable salt thereof.
1~ Various methods for the preparation of Tranilast and pharmaceutically acceptable salts thereof are known (Japanese Patent Application Publication (kokoku) No.Sho.56-40710; ibid.
No.Sho.57-36905; ibid. No.Sho.58-17186; ibid. No.Sho.58-48545;
ibid. No.Sho.58-55138; ibid. No.Sho.58-55139; ibid. No.Hei.
01-28013; ibid. No.Hei.01-50219; ibid. No.Hei.03-37539 etc.).
For example, Tranilast and pharmaceutically acceptable salts thereof can be prepared by allowing a reactive functional derivative such as acid halide and acid anhydride of 3,4-dimethoxyc;nn~m~yl acid represented by the formula:
2~
CHaO~ ( I I ) to react with anthranilic acid represented by the formula:
~ (III) COOH
in the usual way, and if desired, converting the resulting compound into a salt thereof.
As examples of pharmaceutically acceptable salts of Tranilast, salts with inorganic bases such as a sodium salt and a potassium salt, salts formed with organic amines such as morpholine, piperazine and pyrrolidine and salts formed with 1~ amino acids can be illustrated.
When the pharmaceutical compositions of the present invention areemployed in thepractical treatment, various dosage ~orms of pharmaceutical compositions can be used depending upon usage. As examples ofsuch dosage forms,powders, granules, fine granules, dry sirups, tablets, capsules, ointments, injections, eye drops and the like can be illustrated.
These pharmaceutical compositions can be formulated by admixing, diluting or dissolving occasionally with appropriate pharmaceutical additives such as excipients, disintegrators, binders, lubricants, diluents, buffers, isotonicities, antiseptics, moistening agents, emulsifiers, dispersing agents, stabilizing agents and dissolving aids in accordance with conventional methods and formulating in the usual way depending upon the dosage forms.
For example, powders can be formulated by admixing well Tranilast represented by the formula (I) or a pharmaceutically acceptable salt with appropriate excipients, lubricants and the like occasionally.
Tablets can be formulated by admixing Tranilast or a pharmaceutically acceptable salt with appropriate excipients, disintegrators, binders, lubricants and the like occasionally, and pressing the mixture in the usual way. The tablets also can be coated to provide film-coated tablets, sugar-coated tablets, enteric coating tablets and the like.
For example, capsules can be formulated by admixing well appropriate excipients, lubricants and the like occasionally, and filling the mixture in capsules. Capsules can be also formulated by forming granules or fine granules in the usual way, and fi1ling the granules or fine granules in capsules.
Ointments can be used as eye ointments.
Injections can be injected directly into diseased tissues such as cornea and vitreous or their adjacent tissues by using a fine needle, and can be also used as intraocular perfusate.
The pharmaceutical compositions of the present invention can be administered as sustained release preparations. For example, Tranilast preparation is incorporated into pellet or microcapsule of sustained release polymer as a sustained release preparation, andthe pelletormicrocapsule is surgically planted 2~ into tissues to be treated. As examples o~ sustained release polymers, ethylene-vinylacatate copolymer, polyhydro-metacrylate, polyacrylamide, polyvinylpirrolidone, methylcellulose, lactic acid polymer, lactic acid-glycolic acid copolymer and the like can be illustrated, and preferably, biodegradable polymer such as lactic acid polymer and lactic acid-glycolic acid copolymer can be illustrated.
When the pharmaceutical compositions of the present invention are employed in the practical treatment, the dosage of Tranilast or a pharmaceutically acceptable salt thereof as the active ingredient is appropriately decided depending on the body weight, age, sex, degree of symptoms and the like of each patient to be treated, which is ap~roximately within the range of from 100 to 1,000 mg per day per adult human in the case of oral ~m;n;stration and approximately within the range of from 20 ~ g to 300 mg per day per adult human in the case of parenteral administration.
The doseofTranilastor apharmaceutically acceptablesalt thereof can be appropriately increase and decrease depending on the type of diseases, degree of symptoms of each patient to be treated and therapeutic value.
Example Thepresentinventionis furtherillustratedinmoredetail by way of the following Examples.
26 Study to confirm inhibitory effect on neovascularization Example 1 Inhibition of proliferation of human microvascular endothelial cells Culture of human microvascular endothelial cells Normal human dermal microvascular endothelial cells (Cell Systems Corporation) were subcultured in a medium (MVE medium, Cell Systems Corporation) for endothelial cell culture and used for the study. At the logarithmic growth phase, the medium was aspirated and cells were washed with phosphate-buffered saline (PBS(-)) which was added gentlely. Then, the PBS(-) was aspirated, analiquotofO.25% trypsinsolutioncontainingO.02 %
EDTA was added to the culture plate, and the morphology of cells was observed under a phase-contrast microscopy. When cellswere going to be round, an equal value of MVE medium was added to the trypsin solution to stop the action of trypsin. Attached cells 16 were harvested from the plate by pipetting the medium using a slender pasture pipette. Cell suspension was transferred into spit, then medium was added to the spit, and the cell suspension was mixed about 20 times vigorously by pipetting with a pasture pipete and centrifuged at 100-llOxg for 1 minute. A~ter the supernatant was discarded, fresh medium was added to the precipitate, and cell suspension was preparèd by pipetting using a pasture pipete. Number of viable cells in an aliquot of the suspension was counted under a phase-contrast microscopy using a hemocytometer. Cell concentration was adjusted to 2 x 10 26 cells/ml.
Preparation of test drug Tranilast was added to 1 % a~ueous sodium bicarbonate solution to prepare 0.55 % solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and B diluted with MVE medium to a final prescribed concentration.
Experimental method Cell suspension (1 ml) was added to collagen-coated 6-well plate(Toyobo Engineering Co., Ltd.) and cultured at 37 ~C
under a humidified atmosphere of 5 % CO2 in air. After 1 day, the medium was aspirated, cells were washed with PBS(-), and 1 ml of fresh medium and 0.1 ml of various concentrations of Tranilast solution were added to the plate and the plate was incubated for further 2 days. After incubation, the medium was aspirated, cells were washed with PsS(-), and then 1 ml of 0.25 %
trypsin solution cont~ln;ng 0.02% EDTA was added to the plate.
After harvestingcellsfrom theplate bypipettingusing apasture pipete, number ofviable cellswas countedusing ahemocytometer.
~ Assessment of effect Mean and standard variation value o~ each group were calculated. Statistical analysis of significance was performed by a one-way analysis of variance and statistical significance was confirmed. Thereafter, analysis of significance between 2B groups was performed by Dunnett's multiple test.
Results As shown in Figure 1, Tranilast significantly suppressed the proliferation of human microvascular endothelial cells in a concentration-dependent manner.
Example 2 Inhibition of chemotaxis of human microvascular endothelial cells ~ Culture of human microvascular endothelial cells According to the method of Example 1 ~, human microvascular endothelial cells were cultured to prepare a cell suspension. Number of viable cells was counted under a phase-contrast microscopy using a hemocytometer and cell concentration was adjusted to 2 x 10 cells/ml.
Preparation of test drug Tranilast was added to 1 % aqueous sodium bicarbonate solution to prepare 0.55 % solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and diluted with DMEM + Ham (1 : 1) medium to a prescribed final concentration.
Experimental method Chemotaxis of human dermal microvascular endothelial cells (prepared in ~) to vascular endothelial growth factor (VEGF) was studied using a 96-well micro chemotaxis chamber (Neuro Probe Inc.). An aliquot (32 ~ 1) of DMEM + Ham (1:1) medium containing 100 ng/ml of VEGF, 0.1 % bovine serum and various concentrations ofTranilast wasadded tothe lowercavity of the chemotaxis chamber. An aliquot (50 ~ 1) of medium containing cell suspension and Tranilast was added to the upper cavity of the chamber. Polycarbonate filter (10 ~ m thickness with 8 ~ m pore size, Neuro Probe Inc.) coated with type-l collagen was used for the chemotaxis membrane. The chemotaxis chamber was incubated at 37 ~C for 5 hours under a humidified atmosphere of 5 % C02 in air. Cells migrated to the lower side of the filter were fixed with 90 % ethanol, and stained with Diff-Quick (Baxter Diagnostics Inc.). Number of migrated cells was counted in 5 random fields at x 400 magnification under a phase-contrast microscopy and mean chemotaxis cell number was calculated.
Assessment of effect Mean and st~n~rd variation value of each group were calculated. Statistical analysis of significance was performed by a one-way analysis of variance and statistical significance was confirmed. Thereafter, analysis of significance between groups was performed by Dunnett's multiple test.
~ Results 2~ As shown in Figure 2, Tranilast significantly suppressed the chemotaxis of human microvascular endothelial cells in a concentration-dependent manner.
Example 3 Tube formation o~ human microvascular endothelial cells 6 ~ Culture of human microvascular endothelial cells According to the method of Example 1 0, human microvascular endothelial cells were cultured to prepare a cell suspension. Number of viable cells was counted under a phase-contrast microscopy using a hemocytometer and cell concentration was adjusted to 4 x 10 cells/ml.
~Preparation of test drug Tranilast was added to 1~ aqueous sodium bicarbonate solution to prepare 0.5 ~ solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and diluted with MVE medium to a prescribed final concentration.
~Experimental method An aliquot (0.25 ml) of matrigel (10 mg/ml, Becton Dickinson Labware) wasadded to a 24-wellculture plate (Corning) and was then allowed to solidify by incubation at 37 ~C for 1 hour. Suspension (0.25 ml) of human microvascular endothelial cells (4 x 10 cells) and MVE medium (0.25 ml) containing various concentrations of Tranilast were added onto the gel. After 18 hours incubation at 37 ~C, 5 random fields of one well were observed at x lOOmagnificationusingaphase-contrast microscopy and the number of ~ormed network was counted.
Result As shown in Figure 3, number of the formed network was significantly reduced i~ a concentration-dependent manner.
Example 4 Tube ~ormation of human microvascular endothelial cells ~ Culture of human microvascular endothelial cells According to the method of Example 1 ~, human microvascular endothelial cells were cultured to prepare a cell suspension. Number of viable cells was counted under a phase-contrast microscopy using a hemocytometer and cell concentration was adjusted to 4 x 10 cells/ml.
Preparation of test drug Tranilast was added to 1% a~ueous sodium bicarbonate solution to prepare 1.0 % solution and dissolved by warming at 70 ~C. The solution was sterilized with millipore filter and diluted with MVE medium to a prescribed final concentration.
Experimental method An ali~uot (0.25 ml) of matrigel (10 mg/ml, Becton Dickinson Labware) wasadded toa 24-wellculture plate (Corning) and was then allowed to solidify by incubation at 37 ~C for 1 hour. Suspension (0.25 ml) of human microvascular endothelial cells (4 x 10 cells) and MVE medium (0.25 ml) containing various concentrations of Tranilast were added onto the gel. After 18 hours incubation at 37 ~C, 5 random fields of one well were photographed at x 40 magnification using a phase-contrast microscopy. The lengths of the tube structures were measured and the mean value was calculated.
Result As shown in Figure 4, the length of the tube strucure was significantly reduced in a concentration-dependent manner.
Industrial Applicability A pharmaceutical composition comprising as the active ingredient ~ranilast has remarked inhibitory effects on 1~ proliferation and chemotaxis o~ human microvascular endothelial cellsandtubeformationofhumanmicrovascularendothelial cells, and there~ore, is extremely effective as a neovascularization inhibitor.
Claims (6)
1. A neovascularization inhibitor which comprises as the active ingredient N-(3,4-dimethoxycinnamoyl) anthranilic acid represented by the formula:
and a pharmaceutically acceptable salt thereof.
and a pharmaceutically acceptable salt thereof.
2. A neovascularization inhibitor as claimed in claim 1 wherein disease to be treated is diabetic retinopathy.
3. A neovascularization inhibitor as claimed in claim 1 wherein disease to be treated is senile discoid macular degeneration.
4. A method for the prevention and treatment of diseases associated with neovascularization which comprises administering N-(3,4-dimethoxycinnamoyl ) anthranilic acid represented by the formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
5. A use of N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the formula:
or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for the prevention and treatment of diseases associated with neovascularization.
or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for the prevention and treatment of diseases associated with neovascularization.
6. A use of N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the formula:
or a pharmaceutically acceptable salt thereof as a neovascularization inhibitor.
or a pharmaceutically acceptable salt thereof as a neovascularization inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6509496 | 1996-02-15 | ||
| JP8/65094 | 1996-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2246418A1 true CA2246418A1 (en) | 1997-08-21 |
Family
ID=13277001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002246418A Abandoned CA2246418A1 (en) | 1996-02-15 | 1997-02-12 | Neovascularization inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6407139B1 (en) |
| EP (1) | EP0894496A4 (en) |
| KR (1) | KR19990082523A (en) |
| CN (1) | CN1211182A (en) |
| BR (1) | BR9707514A (en) |
| CA (1) | CA2246418A1 (en) |
| CZ (1) | CZ258598A3 (en) |
| EA (1) | EA199800721A1 (en) |
| NO (1) | NO983719L (en) |
| NZ (1) | NZ331339A (en) |
| WO (1) | WO1997029744A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10695353B2 (en) | 2010-11-24 | 2020-06-30 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US11014873B2 (en) | 2017-02-03 | 2021-05-25 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998013038A1 (en) * | 1996-09-28 | 1998-04-02 | Kissei Pharmaceutical Co., Ltd. | Subepithelial turbidity inhibitor |
| AU745028B2 (en) * | 1996-10-14 | 2002-03-07 | Kissei Pharmaceutical Co. Ltd. | Secondary cataract inhibitor |
| IL132391A0 (en) * | 1997-04-18 | 2001-03-19 | Kissei Pharmaceutical | Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells |
| WO2001002344A1 (en) * | 1999-07-01 | 2001-01-11 | Taisho Pharmaceutical Co., Ltd. | Aminobenzoic acid derivatives |
| AU7446600A (en) * | 1999-10-01 | 2001-05-10 | Japan Energy Corporation | Novel diarylamide derivatives and use thereof as medicines |
| US7531575B2 (en) * | 2002-10-31 | 2009-05-12 | Eberhard-Karls-Universität Tübingin | Method of modulating cellular activity and agents useful for same |
| US20050106230A1 (en) * | 2003-11-17 | 2005-05-19 | Young Janel E. | Drug-enhanced adhesion prevention |
| WO2006053390A1 (en) * | 2004-11-17 | 2006-05-26 | Angiogen Pharmaceuticals Pty. Ltd. | A method of modulating b cell functioning |
| US20080009519A1 (en) * | 2004-11-17 | 2008-01-10 | Lawrence Steinman | Method of modulating t cell functioning |
| WO2006122353A1 (en) * | 2005-05-16 | 2006-11-23 | Angiogen Pharmaceuticals Pty. Ltd. | Methods and compositions for the treatment of pain |
| CN101600683B (en) | 2006-07-05 | 2013-06-12 | 法博太科制药有限公司 | Therapeutic compounds |
| JP2008247789A (en) * | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | Medicinal composition for suppressing progress of constriction of intestinal tract accompanied by crohn disease |
| WO2009032202A1 (en) * | 2007-08-29 | 2009-03-12 | Nuon Therapeutics, Inc. | Treatment of brain disorders |
| JP5730578B2 (en) | 2007-12-21 | 2015-06-10 | フィブロテック セラピューティクス プロプライエタリー リミテッド | Halogenated analogs of antifibrotic agents |
| WO2010137681A1 (en) * | 2009-05-29 | 2010-12-02 | 参天製薬株式会社 | Prophylactic or therapeutic agent for retinal diseases comprising tranilast, method for prevention or treatment of retinal diseases, and tranilast or pharmaceutically acceptable salt thereof and use thereof |
| US9592213B2 (en) | 2009-06-17 | 2017-03-14 | National University Corporation Kumamoto University | Prophylactic and/or therapeutic agent for dysmenorrhea |
| CN102574843B (en) | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | Fused ring analogues of anti-fibrotic agents |
| CN102657647A (en) * | 2012-04-06 | 2012-09-12 | 澳门大学 | Application of IC-4 in antiangiogenesis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05163222A (en) * | 1991-12-18 | 1993-06-29 | Kissei Pharmaceut Co Ltd | Therapeutic agent for disease caused by excessive synthesis of collagen |
| JP2617407B2 (en) * | 1992-09-14 | 1997-06-04 | キッセイ薬品工業株式会社 | Preventive and therapeutic agent for intimal cell hyperproliferative disease |
| US5512591A (en) | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
| EP0761251B1 (en) * | 1994-10-17 | 2004-12-29 | Kabushikikaisha Igaki Iryo Sekkei | Drug-releasing stent |
| DE59606488D1 (en) * | 1995-08-31 | 2001-04-05 | Infineon Technologies Ag | Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides |
| DE974350T1 (en) * | 1996-02-07 | 2001-01-25 | Lead Chem Co Ltd | EXTERNAL CONTAINING TRANILAST AND METHOD FOR THE PRODUCTION THEREOF |
-
1997
- 1997-02-12 CA CA002246418A patent/CA2246418A1/en not_active Abandoned
- 1997-02-12 EP EP97902651A patent/EP0894496A4/en not_active Withdrawn
- 1997-02-12 EA EA199800721A patent/EA199800721A1/en unknown
- 1997-02-12 KR KR1019980706259A patent/KR19990082523A/en not_active Application Discontinuation
- 1997-02-12 US US09/125,036 patent/US6407139B1/en not_active Expired - Fee Related
- 1997-02-12 WO PCT/JP1997/000354 patent/WO1997029744A1/en not_active Application Discontinuation
- 1997-02-12 CN CN97192238A patent/CN1211182A/en active Pending
- 1997-02-12 CZ CZ982585A patent/CZ258598A3/en unknown
- 1997-02-12 BR BR9707514A patent/BR9707514A/en not_active Application Discontinuation
- 1997-02-12 NZ NZ331339A patent/NZ331339A/en unknown
-
1998
- 1998-08-13 NO NO983719A patent/NO983719L/en not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10695353B2 (en) | 2010-11-24 | 2020-06-30 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US10786510B2 (en) | 2010-11-24 | 2020-09-29 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US11583535B2 (en) | 2010-11-24 | 2023-02-21 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US11014873B2 (en) | 2017-02-03 | 2021-05-25 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| US11603349B2 (en) | 2017-02-03 | 2023-03-14 | Certa Therapeutics Pty Ltd | Anti-fibrotic compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1211182A (en) | 1999-03-17 |
| EP0894496A4 (en) | 2001-01-03 |
| US6407139B1 (en) | 2002-06-18 |
| WO1997029744A1 (en) | 1997-08-21 |
| NO983719D0 (en) | 1998-08-13 |
| CZ258598A3 (en) | 1998-11-11 |
| KR19990082523A (en) | 1999-11-25 |
| NO983719L (en) | 1998-10-14 |
| NZ331339A (en) | 2001-02-23 |
| EA199800721A1 (en) | 1999-02-25 |
| BR9707514A (en) | 1999-07-27 |
| EP0894496A1 (en) | 1999-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6407139B1 (en) | Neovascularization inhibitor | |
| KR100405285B1 (en) | Pharmaceutical composition comprising synthetic thyroid hormone | |
| WO2006106915A1 (en) | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL CONTAINING PROSTAGLANDIN F2α DERIVATIVE AS ACTIVE INGREDIENT | |
| US5561109A (en) | Method for the healing of wounds caused by corneal injury | |
| US6303655B1 (en) | Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells | |
| US6376543B1 (en) | Secondary cataract inhibitor | |
| US20090221573A1 (en) | Use of Activators of Soluble Guanylate Cyclase for Promoting Wound Healing | |
| EP0974352B1 (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
| AU722807B2 (en) | Neovascularization inhibitor | |
| CN112210891B (en) | Axitinib-loaded nanofiber membrane, preparation method thereof and application thereof in postoperative anti-adhesion | |
| CA2279943C (en) | Treatment of skin disorders | |
| JP2002500170A (en) | Pharmaceutical composition comprising thiram | |
| JP2021511323A (en) | Suspension composition of multi-target inhibitor | |
| JP2005213159A (en) | Neovascularization inhibitor and vascular retraction agent | |
| JP2023552515A (en) | Compositions and methods for treating wounds | |
| TW202400154A (en) | Wound treatment composition | |
| TWI415621B (en) | Usage of interleukin-7 for manufacturing drug of kidney fibrosis and usage of a medication for treatment of kidney fibrosis | |
| JP2688733B2 (en) | Agent for preventing and treating gastrointestinal mucosal disorders | |
| TW200906386A (en) | Compositions with anti-angiogenic activity | |
| JP2004262776A (en) | Angiogenic promoter | |
| JPH11255648A (en) | Vascularization inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |